Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia

American Journal of Hypertension

Volumn 14, Issue 1, 2001, Pages 32-37

  Wierzbicki, Anthony S ^a   Hardman, Timothy C ^b   Cheung, Joseph ^a   Patel, Mayur ^b   Smallberger, Sarah ^b   Lumb, Peter J ^a   Lant, Ariel F ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Familial hyperchylomicronemia; Hypertriglyceridemia; Insulin; Lipoprotein lipase; Sodium lithium countertransport

Indexed keywords

VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; CELL MEMBRANE TRANSPORT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; PRIORITY JOURNAL; SODIUM TRANSPORT; TRANSPORT KINETICS; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPORTERS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; REFERENCE VALUES; TIME FACTORS; TRIGLYCERIDES;

EID: 0035140052     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(00)01228-0     Document Type: Article

References (30)

1. Controversies surrounding sodium-lithium countertransport
2. Increased sodium-lithium countertransport in red cells of patients with essential hypertension
3. Sulphhydryl group control of sodium-lithium countertransport kinetics: A membrane protein control abnormality in essential hypertension
4. Sodium-lithium countertransport and blood pressure change over time: The Gubbio study
5. Increased sodium-lithium countertransport in black non-insulin dependent diabetic hypertensives
6. Relation of sodiumlithium countertransport activity to markers of cardiovascular risk in normotensive subjects
7. Kinetic characteristics of the erythrocyte sodium-lithium countertransporter in subjects with coronary artery disease
8. Is the erythrocyte sodium-lithium countertransporter a molecular marker of cardiac risk in hypertensives?
9. Plasma lipids affect maximum velocity not sodium affinity of human sodium-lithium countertransport: Distinction from essential hypertension
10. Increased sodium-lithium countertransport activity in essential hypertension is due to an increased affinity for extracellular sodium
11. Human lymphocyte sodium-hydrogen exchange, the influence of lipids, membrane fluidity and insulin
12. Sodium-lithium countertransport, sodium-hydrogen exchange and membrane microviscosity in patients with hyperlipidaemia
13. Erythrocyte sodium-lithium countertransport and blood pressure in identical twin pairs discordant for insulin-dependent diabetes mellitus
14. The use of ultracentrifugation for the separation of lipoproteins
15. Measurement and clinical significance of apolipoproteins A-1 and B
16. The determination of Lp(a) by rate and end-point nephelometry
17. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
18. A simple measure of insulin resistance
19. Ethnic origin and hypertension-associated alterations in sodium-lithium countertransport (SLC) kinetics
20. + binding and phospholipid composition in erythrocyte membranes of white hypertensive and normotensive individuals
21. + countertransport: Impact on hypertension and diabetes
22. Insulin modulates sodium-lithium countertransport in vitro not in vivo
23. Effect of exercise on cation transport in human red cells
24. Relations of sodium-lithium countertransport kinetics to plasma and red cell membrane phospholipids in hyperlipidemia
25. Erythrocyte sodium-lithium countertransport activity and total body insulin-mediated glucose disposal in normoalbuminuric normotensive type I (insulin-dependent) diabetic patients
26. Insulin sensitivity, sodium-lithium countertransport and platelet free calcium concentrations in normotensive men with a family history of hypertension
27. Lack of correlation between sodium-lithium countertransport activity and insulin action in non-insulin dependent diabetes mellitus
28. The atherogenic lipoprotein Lp(a) is internalised and degraded in a process mediated by the VLDL receptor
29. Sodium-lithium countertransport and body fat distribution
30. Hyperleptinaemia: The missing link in the metabolic syndrome?